

BURCON EXPANDS EUROPEAN INVESTOR RELATIONS

VANCOUVER, BRITISH COLUMBIA – October 6, 2006 – Burcon NutraScience Corporation (the “Company” or “Burcon”) (TSX-V:BU) announces that it has retained Roderick C. (“Archie”) Adams of London, United Kingdom to perform investor relations services by assisting the Company with communicating its corporate message to European investors. Mr. Adams will complement the existing Burcon Investor Relations program in Europe.

Since 2002 Mr. Adams has been an independent consultant primarily focused on corporate development and finance for early stage companies. He was a founder and is currently the Finance Director of Beckpharma Limited. Beckpharma’s business is to bring Cuban Bio Technology products into Europe, register them and sell them. Previously, Mr. Adams was Director and founder of Jyra Research, a provider of performance monitoring software. He served as Director, Corporate Development officer and was eventually appointed CEO. During this period the organization grew from 2 to 30 employees and achieved a market capitalization of US\$250 million. In addition, Mr. Adams spent 9 years as a Private Client Stockbroker in London.

At Burcon, Mr. Adams will work directly with senior management to broaden the European investors and professionals’ awareness of Burcon. The Investor Relations Service Agreement (the “Agreement”) will have an initial term of 8 months and will automatically renew on its terms for another 12 months unless either the Company or Mr. Adams gives written notice to the other party to renegotiate or terminate the Agreement no less than 30 days prior to the renewal term. The Agreement is also terminable upon 30 days notice by either party. Burcon has agreed to pay Mr. Adams £2,500 per month for performing the services under the Agreement and to reimburse Mr. Adams for his reasonable out-of-pocket expenses. Mr. Adams will also be paid £300 per day for each day he accompanies Burcon’s management on road shows he has arranged for the Company in the United Kingdom or Europe. The Company has also granted Mr. Adams an option to purchase up to a total of 70,000 Common shares in the capital of Burcon at an exercise price of \$2.45 per share. The option will have a term of three years from the date of grant and will vest as to 33 1/3% on the date that is 8, 16 and 24 months from the date of grant, respectively. Mr. Adams does not currently own Burcon securities but may acquire Burcon securities in the future. The Agreement is subject to approval by the TSX Venture Exchange.

“I am excited to have the opportunity to work with Burcon’s management team and equally excited about the considerable potential for the Company’s products, and the Company’s development agreement with Archer Daniels Midland,” commented Mr. Adams. He added, “I look forward to expanding the awareness of Burcon with investors, fund managers and analysts in the European financial community.”

About Burcon NutraScience

Burcon is a research and development company developing a portfolio of composition, application, and process patents around its plant protein extraction and purification

technology. The goal of Burcon's research is to develop its patented process to utilize inexpensive oilseed meals for the production of purified plant proteins that exhibit valuable nutritional, functional, or nutraceutical profiles. Burcon, in conjunction with Archer Daniels Midland, is currently focusing its efforts on developing the world's first commercial canola proteins, Puratein® and Supertein™. Canola, recognized for its nutritional qualities, is the second-largest oilseed crop in the world after soybeans. Burcon's goal is to develop Puratein and Supertein to participate with soy, dairy, and egg proteins in the expanding multi-billion-dollar protein ingredient market, with potential uses in prepared foods, nutritional supplements, and personal care products.

###

ON BEHALF OF THE BOARD OF DIRECTORS

“Johann F. Tergesen”

Johann F. Tergesen

President & Chief Operating Officer

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations regarding the prospect for future success depend upon our ability to develop and sell products, which we do not produce today and cannot be sold without further research and development. When used in this press release, the words “goal,” “intend,” “believes” and “potential” and similar expressions, generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties. In light of the many risks and uncertainties surrounding the development of a source of protein from canola meal, you should understand that we cannot assure you that the forward looking statements contained in this press release will be realized.

For more information, please contact:

Jade Cheng, Chief Financial Officer
Burcon NutraScience Corporation
(604) 733-0896 / (888) 408-7960 toll-free
jcheng@burcon.ca www.burcon.ca

AXINO AG

Sven Olsson, Investor Relations Europe
Silberburgstraße 112, D-70176 Stuttgart, Germany
Tel. +49-711-25 35 92-30 / Fax +49-711-25 35 92-33
olsson@axino.de www.burcon.net